These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 8826659

  • 1. Antilymphocyte induction immunosuppression in the post-Minnesota anti-lymphocyte globulin era: incidence of renal dysfunction and delayed graft function. A single center experience.
    Malinow L, Walker J, Klassen D, Oldach D, Schweitzer E, Bartlett ST, Weir MR.
    Clin Transplant; 1996 Jun; 10(3):237-42. PubMed ID: 8826659
    [Abstract] [Full Text] [Related]

  • 2. Cadaveric kidney transplantation under prophylactic polyclonal antibody immunosuppression with anti-lymphoblast globulin versus anti-thymocyte globulin.
    Indudhara R, Novick AC, Hodge E, Goormastic M, Papajcik D, Mastroianni B, Cook D.
    Urology; 1996 Jun; 47(6):807-12. PubMed ID: 8677568
    [Abstract] [Full Text] [Related]

  • 3. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era.
    Hariharan S, Alexander JW, Schroeder TJ, First MR.
    Clin Transplant; 1996 Apr; 10(2):186-90. PubMed ID: 8664516
    [Abstract] [Full Text] [Related]

  • 4. Prophylaxis of heart transplant rejection with either antithymocyte globulin-, Minnesota antilymphocyte globulin-, or an OKT3-based protocol.
    Ladowski JS, Dillon T, Schatzlein MH, Peterson AC, Deschner WP, Beatty L, Sullivan M, Scheeringa RH, Clark WR.
    J Cardiovasc Surg (Torino); 1993 Apr; 34(2):135-40. PubMed ID: 8320247
    [Abstract] [Full Text] [Related]

  • 5. Clinical impact of replacing Minnesota antilymphocyte globulin with ATGAM.
    Lum CT, Umen AJ, Kasiske B, Goerdt P, Heim-Duthoy KL, Andersen RC, Odland MD, Ney AL, Jacobs DM, Rao KV.
    Transplantation; 1995 Feb 15; 59(3):371-6. PubMed ID: 7871567
    [Abstract] [Full Text] [Related]

  • 6. Quadruple immunosuppression: comparison of OKT3 and Minnesota antilymphocyte globulin.
    Light JA, Khawand N, Aquino A, Ali A, Korb S.
    Am J Kidney Dis; 1989 Nov 15; 14(5 Suppl 2):10-3. PubMed ID: 2510505
    [Abstract] [Full Text] [Related]

  • 7. Comparison of Minnesota antilymphoblast globulin and Upjohn antithymocyte globulin for induction immunosuppression of human renal allografts.
    Pescovitz MD, Book BK, Milgrom ML, Leapman SB, Petersen B, Filo RS.
    Surgery; 1994 Oct 15; 116(4):811-8. PubMed ID: 7940183
    [Abstract] [Full Text] [Related]

  • 8. Comparison of Minnesota antilymphocyte globulin and OKT3 for induction of immunosuppression in renal transplant patients.
    Light JA, Khawand N, Ali A, Brems W, Aquino A.
    Transplant Proc; 1989 Feb 15; 21(1 Pt 2):1738-40. PubMed ID: 2652569
    [Abstract] [Full Text] [Related]

  • 9. A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients.
    Goggins WC, Pascual MA, Powelson JA, Magee C, Tolkoff-Rubin N, Farrell ML, Ko DS, Williams WW, Chandraker A, Delmonico FL, Auchincloss H, Cosimi AB.
    Transplantation; 2003 Sep 15; 76(5):798-802. PubMed ID: 14501856
    [Abstract] [Full Text] [Related]

  • 10. Prevention of rejection and graft loss with an aggressive quadruple immunosuppressive therapy regimen in children and adolescents.
    Conley SB, al-Uzri A, So S, Salvatierra O.
    Transplantation; 1994 Feb 27; 57(4):540-4. PubMed ID: 8116038
    [Abstract] [Full Text] [Related]

  • 11. A randomized prospective trial of prophylactic immunosuppression with ATG-fresenius versus OKT3 after renal transplantation.
    Bock HA, Gallati H, Zürcher RM, Bachofen M, Mihatsch MJ, Landmann J, Thiel G.
    Transplantation; 1995 Mar 27; 59(6):830-40. PubMed ID: 7701577
    [Abstract] [Full Text] [Related]

  • 12. Sequential biological immunosuppression. Induction therapy with rabbit antithymocyte globulin.
    Guttmann RD, Flemming C.
    Clin Transplant; 1997 Jun 27; 11(3):185-92. PubMed ID: 9193840
    [Abstract] [Full Text] [Related]

  • 13. Renal transplantation at the Washington Hospital Center: experience with OKT3 and Minnesota antilymphoblast globulin for induction of immunosuppression.
    Jonsson J, Light JA, Korb SM.
    Clin Transpl; 1990 Jun 27; ():275-88. PubMed ID: 2129409
    [Abstract] [Full Text] [Related]

  • 14. Risk factors and consequences of delayed graft function in deceased donor renal transplant patients receiving antithymocyte globulin induction.
    Patel SJ, Duhart BT, Krauss AG, Moore LW, Egidi MF, Amiri HS, Gaber LW, Gaber AO.
    Transplantation; 2008 Jul 27; 86(2):313-20. PubMed ID: 18645496
    [Abstract] [Full Text] [Related]

  • 15. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
    Woodle ES, Bruce DS, Josephson M, Cronin D, Newell KA, Millis JM, Piper JB, O'Laughlin R, Thistlethwaite JR.
    Clin Transplant; 1996 Aug 27; 10(4):389-95. PubMed ID: 8884115
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of induction therapy in cadaveric renal transplantation comparing rabbit antithymocyte serum and Minnesota antilymphoblast globulin.
    Fisher RA, Tchervenkov JI, Schroeder TJ, Alexander JW, Munda R, Penn I, Carey M, First MR.
    Transplant Proc; 1991 Feb 27; 23(1 Pt 2):1253-5. PubMed ID: 1989203
    [Abstract] [Full Text] [Related]

  • 17. Immunosuppression with antithymocyte globulin in renal transplantation: better long-term graft survival.
    Martins L, Fonseca I, Almeida M, Henriques AC, Dias L, Sarmento AM, Cabrita A.
    Transplant Proc; 2005 Feb 27; 37(6):2755-8. PubMed ID: 16182802
    [Abstract] [Full Text] [Related]

  • 18. A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Decreased rejection and less corticosteroid use with OKT3.
    Renlund DG, O'Connell JB, Gilbert EM, Hammond ME, Burton NA, Jones KW, Karwande SV, Doty DB, Menlove RL, Herrick CM.
    Transplantation; 1989 Apr 27; 47(4):599-605. PubMed ID: 2523099
    [Abstract] [Full Text] [Related]

  • 19. Individualization of immediate posttransplant immunosuppression. The value of antilymphocyte globulin in patients with delayed graft function.
    Matas AJ, Tellis VA, Quinn TA, Glicklich D, Soberman R, Veith FJ.
    Transplantation; 1988 Feb 27; 45(2):406-9. PubMed ID: 3278434
    [Abstract] [Full Text] [Related]

  • 20. Enisoprost in renal transplantation. The Enisoprost Renal Transplant Study Group.
    Adams MB.
    Transplantation; 1992 Feb 27; 53(2):338-45. PubMed ID: 1738927
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.